COA in Progress
Scientific Background & Mechanism
Mechanism of Action / Scientific Background
Vasoactive Intestinal Peptide (VIP) is an endogenous 28-amino-acid neuropeptide found throughout the central and peripheral nervous systems and in several immune and endocrine cell populations. It functions as a neurotransmitter, neuromodulator, secretagogue, vasoregulatory peptide, and immune-signaling molecule.
VIP exerts most of its characterized effects through the class B G-protein-coupled receptors VPAC1 (VIPR1) and VPAC2 (VIPR2). VIP binds both receptors with high affinity. It can also interact with PAC1, although PAC1 generally has substantially greater affinity for PACAP than for VIP.
Activation of VPAC1 and VPAC2 is primarily associated with stimulation of adenylate cyclase, increased intracellular cAMP, and activation of protein kinase A (PKA). Depending on the experimental system, VIP signaling can also influence pathways involving MAP kinases, phospholipase signaling, CREB and NF-κB.
These properties have made VIP useful for investigating neuroendocrine communication, smooth-muscle physiology, epithelial biology, immune regulation and GPCR signaling. Its biological effects are highly dependent on receptor distribution, tissue type and experimental conditions.
Research Applications
Potential laboratory and preclinical research areas include:
VPAC1 receptor signaling
VPAC2 receptor signaling
GPCR pharmacology
cAMP/PKA signaling pathways
Neuroendocrine signaling
Neurotransmitter and neuropeptide biology
Smooth-muscle signaling models
Vascular signaling research
Gastrointestinal physiology
Epithelial-cell signaling
Innate and adaptive immune signaling
Cytokine and chemokine regulation
T-cell differentiation and migration
Macrophage and dendritic-cell research
NF-κB and MAPK pathway studies
Peptide–receptor binding studies
Peptide stability and degradation
Analytical peptide identification
HPLC purity characterization
LC-MS / mass-spectrometry identity analysis
VIP's effects on immune cells have been extensively investigated, including experimental effects involving T-cell differentiation and migration, macrophages, dendritic cells, cytokine production and inflammatory signaling.
VIP is also susceptible to enzymatic degradation, making peptide stability and degradation useful considerations when designing laboratory experiments.
Laboratory Reconstitution Reference
For laboratory research only.
When VIP requires preparation for an analytical or experimental procedure, use an appropriate laboratory-grade solvent or buffer demonstrated to be compatible with the peptide and intended analytical method.
Use calibrated laboratory equipment and appropriate controlled or aseptic handling procedures where required by the research protocol.
Laboratory documentation should record the:
Solvent or buffer used
Prepared laboratory concentration
Preparation date
Sample identifier
Lot / batch number
Storage conditions
Relevant experimental conditions
Prepared research samples should be handled according to validated peptide-stability information and the laboratory's established sample-handling procedures.
Because VIP can undergo enzymatic degradation, researchers should account for peptide stability when establishing sample preparation, storage and analytical procedures.
No human or veterinary dosing, injection, administration, or treatment instructions are provided.
Storage
Store VIP according to conditions established by the applicable product specification, manufacturer documentation and validated peptide-stability information.
Protect research material from conditions that could compromise peptide integrity, including inappropriate temperature, moisture, contamination, excessive light exposure or unnecessary environmental cycling.
Prepared laboratory samples should be maintained under conditions validated for the particular solvent or buffer, concentration, analytical method and experimental duration.
Laboratories should document preparation and storage conditions to maintain appropriate sample traceability and experimental reproducibility.
Scientific References
VIP is well characterized as a 28-amino-acid neuropeptide with widespread expression and diverse physiological functions. Reviews describe its roles as a neurotransmitter, immune regulator, secretagogue and signaling molecule.
Pharmacological research identifies VPAC1 and VPAC2 as the principal high-affinity VIP receptors. Both are class B GPCRs, and their activation is strongly associated with adenylate cyclase and cAMP signaling.
The immune biology of VIP has also been extensively investigated. Experimental literature describes effects involving T cells, macrophages, dendritic cells, cytokine regulation, NF-κB signaling and inflammatory pathways.
Gastrointestinal research additionally describes VIP-mediated regulation of smooth muscle, epithelial processes, secretion and vascular signaling, illustrating the peptide's broad experimental utility.
For your Ivarah Labs VIP 10 mg / 5 mL vial, product-specific claims—including identity, purity percentage, net peptide content, molecular mass, appearance, HPLC results, LC-MS/mass-spectrometry confirmation, sterility, endotoxin testing, microbial testing, or other analytical specifications—should only be populated using results from the corresponding batch-specific laboratory Certificate of Analysis.
Research Use Only — Not for Human Consumption. Not intended for medical, diagnostic, therapeutic, cosmetic, veterinary, respiratory-treatment, immune-treatment, or performance-enhancement use.